• Language
Tell us about your project
Contact us to discuss how we can help you achieve your research goals
Clinical Panels

NovoFocus™ CR

Individuals who are carriers of hereditary pathogenic variants exhibit a higher risk (usually ≥ 50%) of developing cancers during their lifetime. These cancer-related variants are the predisposition to cancer. Therefore, early detection gives you opportunity to maximize health outcomes for your high-risk patients group with patient-tailored screening programs, preventive measures and proactive treatment.

Parameters

NovoFocus™ CR
Cancer Type Multiple Cancers
Sample Type ≥ 5ml Blood
Turnaround Time 15 Calendar Days
Novogene Quality Assurance
Comprehensive Gene Coverage for Herediatary Cancer Screening

Through one sample and one test, NovoFocus™ CR can screen the whole exon regions of the genes which are recommended by international guidelines.

Advanced Technology

Using NGS platform and unique proprietary technology, assess the SNP, InDel, and large fragment deletions at once.

Authoritative Database

Integrated internationally recognized databases to interpret data and generate report.

Competitive Price

With top tier sequencing capacity and superior process efficiency, Novogene offers highly competitive prices for all our services.

Who Benefits from NovoFocus™ CR ?
  • Individuals with a positive family history (several generations) of same or different cancers.
  • Anyone who would like to find out more about their risk of developing cancer.

NovoFocus™ CR Workflow

What Does NovoFocus™ CR Detect?

NovoFocus™ CR contains 106 genes associated with hereditary cancers. The genes are carefully selected with the potential risks of developing one or more of the following hereditary tumors.

Associated Genes Across 8 Important Hereditary Cancer Types
Genes Breast Ovarian Colorectal Uterine Renal Pancreatic Gastric Prostate Others
APC
ATM
AXIN2
BARD1
BRCA1
BRCA2
BRIP1
BUB1
BUB1B
BUB3
CDH1
CDKN2A
CHEK2
ELAC
EPCAM
FH
FLCN
HNF1A
HOXB13
MET
MLH1
MLH3
MSH2
MSH6
MUTYH
NBN
PALB2
PMS1
PMS2
PRSS1
PTEN
RAD51C
RAD51D
RNASEL
SDHA/SDHB
SDHC/SDHD
SMAD4
STK11
TP53
VHL

Data Interpretations

(*OMIM Database and NCCN Guidelines)

Positive Results Uncertain Variants Negative Results
Pathogenic/Likely pathogenic Medical Management Based on Recommendations for the Specific Variants Uncertain Significance Variant Surveillance and Medical Management Based on Personal/Family Cancer History Likely benign/Benign Recommendations based on general population cancer risk screening